Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery

Head and Neck - Tập 25 Số 11 - Trang 953-959 - 2003
Lai‐San Wong1, WI Wei1, Lai Kun Lam1, Anthony Po Wing Yuen1
1Division of Otorhinolaryngology, Department of Surgery, Queen Mary Hospital, Pokfulam Road, Hong Kong, China

Tóm tắt

AbstractPurpose.

The efficacy of salvage treatment of recurrent head and neck squamous cell carcinomas (HNSCC) after primary curative surgery was evaluated.

Methods.

The management outcome of 377 patients who had recurrent squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, and larynx after primary curative surgery was reviewed.

Results.

The surgical salvage rates of recurrence were 29% local, 30% tracheostomal, 56% unilateral nodal recurrence of previously undissected neck, 32% of unilateral neck recurrence after prior neck dissection, and 11% lung metastasis. The 5‐year tumor‐free actuarial survival rates of those patients who received surgical salvage was 35% for local recurrence, 32% for unilateral nodal recurrence of the previously undissected neck, and 18% for nodal recurrence of the previously dissected neck. One patient of six with tracheostomal recurrence salvaged with surgery and one patient of six with lung metastasis salvaged with lobectomy survived without tumor at 5 years. There was no 5‐year survivor of all patients salvaged with other nonsurgical methods. The mean survival of patients without surgical salvage was 6 months.

Conclusions.

There was a moderate chance of cure after surgical salvage of locoregional recurrent HNSCC. Surgical salvage was, however, only feasible for early recurrent tumor. Close follow‐up surveillance of early recurrence is essential after primary treatment of patients. © 2003 Wiley Periodicals, Inc. Head and Neck 25: 000–000, 2003

Từ khóa


Tài liệu tham khảo

10.1002/bjs.1800610905

10.1016/0002-9610(76)90314-7

10.1016/0002-9610(76)90328-7

10.1001/archotol.1992.01880050029006

Yuen APW, 1995, Analysis of recurrence after surgical treatment of advanced laryngeal carcinoma, J Laryngol Otol, 109, 1063, 10.1017/S0022215100132037

10.1002/hed.2880170610

10.1016/S0196-0709(96)90070-8

10.1016/S0748-7983(96)90198-5

10.1177/014556139807700307

Aldelstein D, 1994, The community approach to salvage therapy for advanced head and neck cancer, Semin Oncol, 21, 52

10.1002/(SICI)1097-0347(200001)22:1<34::AID-HED6>3.0.CO;2-3

10.1288/00005537-198808000-00020

10.1016/S0002-9610(97)00282-1

10.1016/S0002-9610(96)00162-6

10.1111/j.1365-2273.1995.tb00032.x

10.1001/archsurg.1979.01370250041008

10.1016/S0002-9610(98)00294-3

10.1002/(SICI)1097-0347(199710)19:7<583::AID-HED4>3.0.CO;2-3

10.1001/archotol.1996.01890190038010

10.1016/S0002-9610(00)00433-5

10.1002/hed.10094

10.1046/j.1365-2273.2001.00441.x

10.1007/s004320000177

10.1002/hed.1032

10.1002/1097-0142(197707)40:1<145::AID-CNCR2820400124>3.0.CO;2-9

10.1002/(SICI)1097-0347(199709)19:6<500::AID-HED7>3.0.CO;2-2

10.1016/0002-9610(89)90020-2

10.1288/00005537-198002000-00002

10.1002/(SICI)1097-0347(199607/08)18:4<311::AID-HED1>3.0.CO;2-0

10.1016/S0002-9610(88)80282-4

10.1016/S0002-9610(05)80714-7

Wong S, 2002, High frequency of promoter hypermethylation of the Death‐Associated Protein (DAP)—Kinase gene in nasopharyngeal carcinoma its detection in peripheral blood of patient, Clin Cancer Res, 8, 433

Rosas SL, 2001, Promoter hypermethylation patterns of p16, O6‐methylguanine‐DNA‐methyltransferase, and death‐associated protein kinase in tumors and saliva of head and neck cancer patients, Cancer Res, 61, 939

Palmisano WA, 2000, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res, 60, 5954